medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2020, Number 3

<< Back Next >>

Residente 2020; 15 (3)

Metabolic syndrome and nefrolitiasis association

Oseguera-Brizuela MA

Language: Spanish
References: 12
Page: 89-96
PDF size: 270.07 Kb.


ABSTRACT

The prevalence of kidney stones are doubled in the last three decades, is one of the principal causes of morbidity and has a high economic impact. The pathophysiology of stone formation is a complex process that includes many components like low urinary volume, hypercalciuria, hyperoxaluria, hypocitraturia, urinary pH abnormalities, there are importantly related to the components of the metabolic syndrome, and on the other hand, it is related with the most frequent types of stones in this type of patients. The components of metabolic syndrome has an important impact on the metabolism of patients who suffer this diseases, causing changes that bring more risk to develop kidney stones, these patients have a high risk of suffering from various aggregate diseases, among which are cardiovascular diseases, renal failure, and many diseases of the urinary tract, which is one of the most affected by the obstruction and it have an epithelial risk caused by the lithos. The treatment of nephrolithiasis in patients with metabolic syndrome, focuses on modifying and reversing all these changes that these patients present, the treatment is composed of changes in the patient’s lifestyle , and drugs that help in the modification of this factors that are altered in them.


REFERENCES

  1. Wong Y, Cook P, Roderick P, Bk S. Metabolic syndrome and kidney stone disease: a systematic review of literature. J Endourol. 2016; 30 (3): 246-253.

  2. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens. 2008; 17 (3): 304-309.

  3. Boyd C, Wood K, Whitaker D, Assimos DG. The influence of metabolic syndrome and its components on the development of nephrolithiasis. Asian J Urol. 2018; 5 (4): 215-222. Available from: https://doi.org/10.1016/j.ajur.2018.06.002.

  4. Dibianco JM, Jarrett TW, Mufarrij P. Metabolic syndrome and nephrolithiasis risk: should the medical management of nephrolithiasis include the treatment of metabolic syndrome? Rev Urol. 2015; 17 (3): 117-128.

  5. Lange JN, Mufarrij PW, Wood KD, Holmes RP, Assimos DG. The association of cardiovascular disease and metabolic syndrome with nephrolithiasis. Curr Opin Urol. 2012; 22 (2): 154-159.

  6. Spatola L, Angelini C, Badalamenti S, Maringhini S, Gambaro G. Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences. Urolithiasis. 2017; 45 (5): 457-460.

  7. Khan SR. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res. 2012; 40 (95): 95-112.

  8. Sharaf UA, Din E, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017; 8 (5): 537-548. Available from: http://dx.doi.org/10.1016/j.jare.2016.11.004.

  9. Shadman A, Bastani B. Kidney Calculi: Pathophysiology and as a systemic disorder. Iran J Kidney Dis. 2017; 11 (3): 180-191.

  10. Carbone A, Salhi YA, Tasca A, Palleschi G, Fuschi A, Nunzio CD et al. Obesity and kidney stone disease: a systematic review. Minerva Uologica Nefrol. 2018; 70 (4): 393-400.

  11. Ticinesi A, Guerra A, Allegri F, Nouvenne A. Determinants of calcium and oxalate excretion in subjects with calcium nephrolithiasis: the role of metabolic syndrome traits. J Nephrol. 2018; 31: 395-403. Available from: http://dx.doi.org/10.1007/s40620-017-0453-3.

  12. Dhondup T, Kittanamongkolchai W, Vaughan LE, Mehta RA, Chhina JK, Enders FT et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am J Kidney Dis. 2018; 72 (6): 790-797. Available from: https://doi.org/10.1053/j.ajkd.2018.06.012.




2020     |     www.medigraphic.com